Control on the Illegal Use of Clenbuterol in Pigs In Hong Kong by Sit, Thomas & Tam, Gloria
230
ORAL PRESENTATIONS
ORAL PRESENTATIONS
coli levels, suggesting that alternative methods of slurry application may be considered in MRDT104
infected swineherds, regardless of infection level. The different pattern of decay for slurry injection
is due to a sampling error on day 0. Linear extrapolation suggests that the actual E. coli counts on
this plot on day 0 probably were at least log 3.5 cfu/g. This study also provided input parameters for
a simulation model estimating survival of Salmonella when slurry from clinically and subclinically
infected swineherds is applied to arable land (see Alban & Boes, in this issue). 
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Clenbuterol is a beta-agonist normally used for the treatment of chronic obstructive pulmonary
disease in horses (Adams 1984) and management of parturition in cattle and sheep (Sasse 1987).
However, it also has leanness-enhancing effects when included in the feed of several livestock species,
including swine (Ricks et al., 1984: Anderson et al., 1990; Mersmann, 1998).  Studies on improved growth
promotion associated with beta-agonist in feed first appeared in the literature in the early 1980s
(Baker and Kiernan 1983, Baker et al. 1984) Significant improvements in food conversion ratio were
found in a large range of livestock species, including cattle (Allen et al. 1997), sheep (Hanrahan et
al. 1987), pigs (Jones et al. 1985) and poultry (Dalrymple and Ingle 1987).
Clenbuterol has not been approved as a feed additive by many countries in the world because its
residues remain in tissues of treated cattle and pigs and resulted in human poisonings (Pulce et al., 1991;
Salleras et al., 1995; Sporano et al., 1998).  Levels of clenbuterol in animal tissues have been reported to
range from 375 to 500 ppb in calf liver (Pulce et al., 1991) to 500 ppb in calf muscle (Maistro et al, 1995).
To minimize the potential risk to public health, a maximum permitted residue level of 0.5 ug/kg has been
introduced by the European Union (EU) in 1992 (Report, 1992).  In North America, the illegal use of
clenbuterol came to the attention of meat inspection officials in the United States and Canada in 1988
(Mitchell 1997 CVM).  In 1991, the Food Safety and Inspection Service of the US Department of Agriculture
announced that it would condemn meat tested positive for clenbuterol residues.
Although many countries have banned the use of clenbuterol as a growth promoter, the economic
advantage associated with its use has encouraged the continued abuse of this and other beta-
agonists.  In 1993, monitoring programmes in EU countries for beta-agonists detected between 0%
(UK, France and Denmark) to 7% (Italy) positive samples (Kuiper et al. 1997). 
In Hong Kong, clenbuterol hydrochloride is not registered as a pharmaceutical product for use in
livestock.  However, in May 1998, a number of citizens developed tremor and palpitation after
consuming pig offal containing clenbuterol residues.  Live pig and meat traders were approached
for withdrawal of pig offal from sale.  Later in August, a rapid testing programme was introduced in
slaughterhouses to screen out pigs fed with clenbuterol coupled with a tattoo identification system
to trace pigs to their farms of origin.  The system proved to work effectively.  Pigs tested positive were
detained and could be traced back for further management, including possible prosecution of their
owners.
From 1999 to 2002, over nine million live pigs were slaughtered for local consumption in Hong Kong.
All pigs must be screened negative for beta-agonists before being slaughtered.  Urine samples were
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used and subject to using a commercial enzyme immunoassay, with positive results confirmed by
testing meat samples using gas chromatography-mass spectrometric analysis.
The numbers of urine samples taken were 56,331, 60,861, 85,318 and 71,716 in the years 1999, 2000,
2001 and 2002 respectively.  The percentages of positive samples were 0.98, 0.59 and 0.23 from 1999
to 2001.  For pigs with positive results, the whole consignment was detained for investigation.  Since
August 1998, the rate of contaminated offal at slaughterhouses dropped significantly from 6.6%
before the system was implemented, to less than 1% soon after.  With the introduction of a new
legislation on 31 December 2001 to legalize the above protocol, there were only four (4) positive
samples for clenbuterol in 2002.
Very few studies have been published on the total residues remaining in edible tissues of pigs treated
with clenbuterol.  The period for which drug residues remain detectable in an animal is dependent
on the dose administered, the duration of exposure and the persistence in target tissues (Elliott 1994).
There is a 15-day withdrawal period following the therapeutic use of clenbuterol, and residues can
still be detected in the livers of treated cattle 14 days after administration (Meyer and Rinke 1991).
Other studies have also shown that the liver is the target site for detection of clenbuterol residue
persistence (Elliott et al., 1993).  Therefore, pig meat and offals are also monitored in slaughterhouses
and retail outlets for evidence of clenbuterol or salbutamol contamination in case pig farmers try to
evade detection by the ante-mortem urine screening system.
14,253 meat and offal samples were taken between 1999 and 2001.  1.3% of 3,638 samples, 1.3%
of 4,893 samples and 0.5% of 5,722 samples tested positive for both clenbuterol and salbutamol
in the years 1999, 2000 and 2001 respectively.  The results showed a marked decrease from 1999
to 2001.  The highest levels of clenbuterol recorded in positive offals were 2,000 ppb in lung and
520 ppb in liver in retail shops.  However, samples taken at slaughterhouse in 2000 averaged less
than 5 ppb.  Comparing the surveillance results from slaughterhouses and retail outlets, there
was a significant difference in positive samples, with the latter having almost twice as many
positive samples.  This exposed the suspicion that some retail outlets might have obtained their
pork and offal from illegal sources.  During 1998-1999, 40 consignments of  pigs (340 total) were
seized from illegal slaughterhouses, and 70% of such animals tested showed a high positive
percentage for clenbuterol in urine.  The concentrations of clenbuterol and salbutamol in urine
and other internal organs were measured for two batches of pigs seized at local slaughterhouses
with positive results.  The results (Figs 1a and b) indicated variable concentrations in internal
organs of clenbuterol and salbutamol, suggesting that both substances had been used.  The liver
and lung were the preferable target organs for clenbuterol detection.  Another study was performed
in four batches of pigs which had tested positive for beta-agonists at slaughterhouses on the
time required for excretion of clenbuterol. (Figs 2a, b, c & d).  The urine concentration of clenbuterol
took only 14 hrs to fall from a detectable level (25 ppb) to undetectable level, using commercial
screening tests (Fig 2a).  For higher concentrations in urine (Fig 2b), Pig 2 with 45 ppb clenbuterol
in its urine required 30 hours to fall to less than 5 ppb which is the usually adopted cut off point
for beta-agonist screening so as to avoid false positive cases.  In Fig 2c, the concentration of
clenbuterol in urine of Pig 2 increased from less than 5 ppb to greater than 52 ppb.  This indicated
the concentration of clenbuterol in urine may vary with the water intake of the animal, or there
are other factors affecting the metabolism of animals fed with clenbuterol.  In some cases when
pigs were fed excessive amount of clenbuterol (Fig 2d), the urine level remains detectable for 72
hours.  The results of these monitoring studies show that illegally treated animals would likely have
variable levels of clenbuterol in their urine and that they may not always be identifiable by pre-
slaughter screening.
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Figure 1a: Studies of concentration of clenbuterol in internal organs and urine of one batch of pigs fed seized
at slaughterhouses
Figure 1b: Concentration of clenbuterol in internal organs and urine on second batch of pigs seized at
slaughterhouse
Figure 2a
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Figure 2b 
Figure 2c
234
ORAL PRESENTATIONS
ORAL PRESENTATIONS
Figure 2d 
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